Anti-Ro52 antibodies are commonly found in patients with MDA5 antibody-positive dermatomyositis (MDA5-DM), and elevated levels of these antibodies are associated with decreased survival rates (Wang et al., 2023). Here, TRIM21 is linked to dermatomyositis.